0000105770-26-000049
SEC filingQ1 2026 delivered exceptional profitability with operating income up 66% to $177.1M on 21% revenue growth to $844.9M, driven by strong demand and leverage, though moderated by higher corporate costs and moderated cash generation from investments and repurchases.
Revenue grew 21.0% to $844.9 million in Q1 2026 from $698.0 million a year ago, propelled by higher net sales volumes. This demand strength accelerated sales into the March 31 quarter-end, increasing accounts receivable balances compared to December 31, 2025. The revenue expansion provided a solid foundation for margin leverage across the P&L.
Gross profit expanded 27.8% to $296.4 million, achieving a 35.1% margin on the higher revenue base. Within this, the West Vantage gross profit margin decreased by 0.6 percentage points year-over-year, primarily due to increased production costs. Sales price increases partially offset these pressures, underscoring pricing discipline amid elevated input expenses. Management commentary flags potential future inflationary pressures from Middle East tensions, though not expected to be material. Overall, gross margins demonstrate resilience as volume growth absorbs fixed costs effectively.
Operating income more than doubled, rising 65.5% to $177.1 million and representing a 21.0% operating margin—up significantly from the prior year. This surge reflects potent operational leverage from revenue gains outpacing cost increases. Corporate SG&A costs rose notably due to higher stock-based compensation and salary/wages, contributing to the dynamic where topline growth and gross margin stability drove bottom-line acceleration despite overhead expansion.
These profitability gains flowed through to net income, which increased 54.6% to $138.8 million, with diluted EPS advancing 56.1% to $1.92 from $1.23. The consistent leverage across metrics highlights efficient cost control and demand fulfillment in West's specialized pharmaceutical components business.